Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.47 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.47 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.47 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | GRK2 | P25098 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9320853 | 0.92 | GAA (0.62) | ALDH1A1GAATP53HTTHSD11B1 | |
| SCHEMBL4820396 | 0.84 | GAA (0.59) | ALDH1A1GAATP53HTTHSD11B1 | |
| SCHEMBL11727133 | 0.83 | HDAC1 (0.61) | HSD11B1HDAC1HDAC8KMT2ALMNA | |
| Acetic Acid SCHEMBL10581041 | 0.82 | HTT (0.60) | ALDH1A1HTTHSD11B1NPSR1PLAAT3 | |
| Acetic Acid SCHEMBL10578543 | 0.82 | HDAC1 (0.53) | ALDH1A1GAAHTTHDAC1HDAC8 | |
| SCHEMBL10580731 | 0.82 | HDAC1 (0.56) | ALDH1A1HSD11B1HDAC1HDAC8KMT2A | |
| SCHEMBL3250400 | 0.82 | TBXA2R (0.62) | ALDH1A1GAATP53HTTHSD11B1 | |
| SCHEMBL10583129 | 0.80 | TBXA2R (0.52) | ALDH1A1GAATP53HTTHSD11B1 | |
| SCHEMBL362669 | 0.80 | ALDH1A1 (0.54) | ALDH1A1GAAHTTKMT2ANPSR1 | |
| SCHEMBL10995947 | 0.80 | HDAC1 (0.63) | ALDH1A1HSD11B1HDAC1HDAC8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0357030-B1 | Use of thromboxane A2 receptor antagonists for the preparation of a pharmaceutical composition for treating skin injuries | SQUIBB & SONS INC (US) | 1994-01-19 | — | — | EP | claimed |
| EP-0337697-B1 | USE OF A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING PULMONARY HYPERTENSION CAUSED BY PROTAMINE INDUCED NEUTRALIZATION OF HEPAMIN | SQUIBB & SONS INC (US) | 1993-08-04 | — | — | EP | claimed |
| EP-0309801-B1 | USE OF THROMBOXANE A2 ANTAGONISTS FOR THE MANUFACTURE OF A MEDICAMENT FOR IMPROVING POST-ISCHEMIC MYOCARDIAL DYSFUNCTION | E.R. Squibb & Sons, Inc. (US) | 1993-05-12 | — | — | EP | claimed |
| US-H1139-H | Reduced myocardial infarction size and angina pain; prevention of reocclusion with no adverse side effects | E. R. SQUIBB & SONS, INC. (US) | 1993-02-02 | — | — | US | claimed |
| EP-0340008-B1 | METHOD OF PREVENTING OR REDUCING VENOUS THROMBOSIS USING A THROMBOXANE A2 RECEPTOR ANTAGONIST IN CONJUNCTION WITH HEPARIN AND COMBINATION | SQUIBB & SONS INC (US) | 1992-10-14 | — | — | EP | claimed |
| EP-0351755-B1 | COMBINATION OF A CALCIUM CHANNEL BLOCKER AND THROMBOXANE A2 RECEPTOR ANTAGONIST OR SYNTHETASE INHIBITOR AND METHOD FOR TREATING ISCHEMIA EMPLOYING SUCH COMBINATION | E.R. SQUIBB & SONS, INC. (US) | 1992-09-30 | — | — | EP | claimed |
| US-5066480-A | Treating pulmonary hypertension caused by protamine induced neutralization of heparin | E. R. SQUIBB & SONS, INC. (US) | 1991-11-19 | — | — | US | claimed |
| US-4931460-A | ADMINISTERING 7-OXA-BICYLOHEPTANE PROSTAGLANDIN ANALOGS | E. R. SQUIBB & SONS, INC. (US) | 1990-06-05 | — | — | US | claimed |
| US-4925873-A | PROSTAGLANDIN DERIVATIVES OR SUBSTITUTED PHENYLACETIC ACIDS | E. R. SQUIBB & SONS, INC. (US) | 1990-05-15 | — | — | US | claimed |
| EP-0357030-A2 | Use of thromboxane A2 receptor antagonists for the preparation of a pharmaceutical composition for treating skin injuries | E.R. SQUIBB & SONS, INC. (US) | 1990-03-07 | — | — | EP | claimed |
| EP-0351755-A1 | Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination | E.R. SQUIBB & SONS, INC. (US) | 1990-01-24 | — | — | EP | claimed |
| EP-0340008-A1 | Method of preventing or reducing venous thrombosis using a thromboxane A2 receptor antagonist in conjunction with heparin and combination | E.R. SQUIBB & SONS, INC. (US) | 1989-11-02 | — | — | EP | claimed |
| EP-0337697-A2 | Use of a thromboxane A2 receptor antagonist for the manufacture of a medicament for treating pulmonary hypertension caused by protamine induced neutralization of hepamin | E.R. SQUIBB & SONS, INC. (US) | 1989-10-18 | — | — | EP | claimed |
| EP-0332306-A2 | Preventing platelet loss using a thromboxane A2 receptor antagonist | E.R. Squibb & Sons, Inc. (US) | 1989-09-13 | — | — | EP | claimed |
| US-4857548-A | Method of preventing or reducing platelet loss during extracorporeal circulation using a thromboxane A2 receptor antagonist | E. R. SQUIBB & SONS, INC. (US) | 1989-08-15 | — | — | US | claimed |
| EP-0320935-A2 | Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist | E.R. Squibb & Sons, Inc. (US) | 1989-06-21 | — | — | EP | claimed |
| EP-0309801-A2 | Use of thromboxane A2 antagonists for the manufacture of a medicament for improving post-ischemic myocardial dysfunction | E.R. Squibb & Sons, Inc. (US) | 1989-04-05 | — | — | EP | claimed |
| US-4808627-A | Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist | E. R. SQUIBB & SONS, INC. (US) | 1989-02-28 | — | — | US | claimed |
| US-20250114334-A1 | Ifetroban Treatment for Systemic Sclerosis | VANDERBILT UNIVERSITY | 2025-04-10 | — | — | US | disclosed |
| EP-0297768-A1 | Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use | E.R. Squibb & Sons, Inc. (US) | 1989-01-04 | — | — | EP | disclosed |